("Kyoto iCAP"), a portfolio company of Kyoto University Innovation Capital Corporation (Headquarters: Sakyo-ku, Kyoto, Japan; Representative Director: Ko Kusumi), announced that on September 15, 2022 (EST), Lisata Therapeutics, Inc. (Nasdaq: LSTA) on September 15, 2022 (EST). This is the first overseas listing for a company supported and invested in by Kyoto iCAP's investment funds. At the time of the listing, Kyoto iCAP will be the largest shareholder of Lisata, excluding management and founders.

Lisata is the result of the merger of equals between Cend Therapeutics ("Cend") and Caladrius Biosciences ("Caladrius", Nasdaq: CLBS). Cend was founded by Dr. Erkki Ruoslahti (currently Distinguished Professor Emeritus at the Sanford Burnham Institute), the discoverer of the cell adhesion factor integrin, and has in its pipeline Cend-1, which enables high molecular weight drugs such as antibodies and cellular drugs to penetrate deep into solid tumors. The company has completed a PIb study of Cend-1 in combination with standard therapy for pancreatic cancer (Lancet Gastroenterol. Hepatol.2022; 7: 943-951) and is currently conducting a PIIb study. In collaboration with F. Hoffman-La Roche Ltd. ("Roche"), the Company has decided to initiate a PIb/II study in metastatic pancreatic cancer in combination with Roche's PD-L1 antibody, atezolizumab (Tecentriq®), an immune checkpoint inhibitor. The study will be conducted in combination with atezolizumab (Tecentriq®), a high molecular weight anti-tumor. The drug is expected to expand the indication for high molecular weight anti-tumor drugs and reduce toxicity, and is expected to have broad application as a first-line combination drug.Cend has entered into a basic agreement with Kyoto University to conduct joint non-clinical/clinical trials, and Kyoto iCAP is executing its investment in the company in March 2019.

Caladrius has XOWNA® (CLBS16), a cardiovascular drug, and HONEDRA® (CLBS12), a drug for the treatment of Critical Limb Ischemia (CLI) and Buerger's disease, which has received Pioneer Drug Designation in Japan, and both are in clinical trials. Lisata also has a CD34+ cell therapy (CLBS201) in the pipeline for diabetic kidney disease (DKD).

Lisata Therapeutics, Inc.

Establishment	2015 (Cend Inc.), 1980 (Caladrius Inc.)
Business	Biopharmaceutical Research and Development
Head Office Location	New Jersey, U.S.A.
President & CEO	David J. Mazzo, Ph.